Showing results (21-30 of 240) with videos related to
Sort By:
Pageof 24
Anti-Cancer Drugs|July 3, 2008
Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II and pharmacokinetic study in JapanNahomi Tokudome, Yoshinori Ito, Kiyohiko Hatake, et al.Cancer Chemotherapy and Pharmacology|July 15, 2010
The efficacy and safety of gemcitabine plus paclitaxel combination first-line therapy for Japanese patients with metastatic breast cancer including triple-negative phenotypeKenjiro Aogi, Masayuki Yoshida, Yoshiaki Sagara, et al.The Journal of Steroid Biochemistry and Molecular Biology|November 19, 2003
Role of steroid sulfatase in local formation of estrogen in post-menopausal breast cancer patientsTaisuke Nakata, Shigemitsu Takashima, Yukimasa Shiotsu, et al.Japanese Journal of Clinical Oncology|September 25, 2009
Phase II study of gemcitabine monotherapy as a salvage treatment for Japanese metastatic breast cancer patients after anthracycline and taxane treatmentYasuhiro Suzuki, Yutaka Tokuda, Yasuhiro Fujiwara, et al.International Journal of Clinical Oncology|February 25, 2005
A Japanese phase I study of continuous oral capecitabine in patients with malignant solid tumorsToshiaki Saeki, Shigemitsu Takashima, Masanori Terashima, et al.Gan to Kagaku Ryoho. Cancer & Chemotherapy|November 22, 2019
[The Version 2.0 Practice Guideline for Anti-Emetic and Standard Therapy]Toshiaki SaekiBreast Cancer (Tokyo, Japan)|January 15, 2003
What is the Japanese consensus on adjuvant chemotherapy in breast cancer?Toshiaki SaekiGan to Kagaku Ryoho. Cancer & Chemotherapy|August 11, 2006
[Clinical benefit of S-1 in metastatic breast cancer]Toshiaki SaekiInternational Journal of Clinical Oncology|March 1, 2008
No increase of breast cancer incidence in Japanese women who received hormone replacement therapy: overview of a case-control study of breast cancer risk in JapanToshiaki Saeki, Muneo Sano, Yoshifumi Komoike, et al.Gan to Kagaku Ryoho. Cancer & Chemotherapy|June 23, 2010
[An antiemetic guideline for patients with malignancies in Japan]Hideki Takeuchi, Toshiaki SaekiPageof 24